Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Utidelone Injection plus Gemcitabine in First-line Metastatic Pancreatic Adenocarcinoma
ChiCTR2300077853Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Nov 2023
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of utidelone and gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate (ORR). Started Nov 2023; status: recruiting.
02
Drugs
utidelonegemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2300077853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077853.